SOURCE: Eugene Science, Inc.

March 01, 2007 08:30 ET

Eugene Science Signs Investment Banking Agreement With Dawson James Securities

LOS ANGELES, CA -- (MARKET WIRE) -- March 1, 2007 -- Eugene Science (OTCBB: EUSI), developer and marketer of advanced health supplements & nutraceutical products, announced today it has entered into an Investment Banking Agreement with Dawson James Securities. Under the terms of the agreement, Dawson James will render consulting services to Eugene Science relating to financial advisory services, investment banking and assisting the Company with merger and acquisition matters.

About Dawson James Securities, Inc.

Dawson James Securities is an independent, registered full-service investment banking firm, specializing in the complex and fast-moving healthcare, biotechnology and technology sectors. For more information, visit http://www.dawsonjames.com.

About Eugene Science, Inc.

Based in Bucheon, Kyunggi-Do, Korea, Eugene Science is a global biotechnology company tackling ailments such as heart disease, obesity and diabetes through innovation in the nutraceutical field. Its first commercial heart disease product, CZ™, is a patented, nanoscience-based, water-soluble functional food ingredient containing natural plant sterols that help maintain healthy cholesterol levels by inhibiting its absorption. CZ™ is available in capsule form, or as a food or beverage additive. Plant sterols are approved by the U.S. FDA for health claims related to cholesterol lowering efficacy. For additional information on Eugene Science please visit: http://www.eugene21.com

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition, from time to time, Eugene Science, or its representatives, have made or may make forward-looking statements, orally or in writing. The words "estimate," "project," "potential," "intended," "expect," "anticipate," "believe" and similar expressions or words are intended to identify forward-looking statements. Such forward-looking statements may be included in, but are not limited to, various filings made by Eugene Science with the United States Securities and Exchange Commission (available at www.sec.gov), press releases or oral statements made with the approval of an authorized executive officer of Eugene Science. Actual results could differ materially from those projected or suggested in any forward-looking statements as a result of a wide variety of factors and conditions. Reference is hereby made to Eugene Science's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2005 for information regarding those factors and conditions. Among the important factors that could cause actual results to differ materially from management's projections, estimates and expectations include, but are not limited to: changing economic influences in the nutraceutical industry; dependence on key personnel; actions of third parties; the market for CholCare™ capsules and other company products, and availability of adequate financing. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only as of the date of this press release. Eugene Science undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Contact Information

  • For Further Information
    Mirador Consulting, Inc.
    Frank Benedetto
    Phone 561-989-3600